Table 2. Patient characteristics and... | American Society of Hematology

Table 2.

Patient characteristics and incidence of ejection fraction reduction ≥20% for different carfilzomib-based regimens

Characteristic	KRd (%)(n = 17)		Kd (%)(n = 31)		KMP (%)(n = 12)
Characteristic	No.	%	No.	%	No.	%
Ejection fraction reduction ≤20%		6		13		17
Age >65 y		82		68		100
Sex
Male		35		87		50
Female		65		13		50
No. of prior treatments (range)	2 (1-3)		2 (1-7)		0
NDMM		0		0		100
RRMM		100		100		0
Prior high-dose therapy		53		71		0
Prior anthracyclines		41		45		0
Bortezomib		65		84		0
Immunomodulatory imide drugs		77		87		0
Cardiovascular risk factors
Smoking		29		55		42
Hypertension		29		32		58
Coronary artery disease		6		6.5		8
Peripheral artery disease		29		23		33
Diabetes mellitus		18		23		25
Hyperlipidemia		13		12		50
Stroke		6		3		17
Arrhythmias		0		10		8
Cardiovascular disease (coronary artery disease, peripheral artery disease, stroke)		29		26		33
Medication
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers		29		19		58
Calcium channel blockers		12		13		33
Beta blockers		12		16		25
Diuretics		24		13		25
Estimated glomerular filtration rate, mL/min/1.73 m²	91		91		58
*Cafilzomib dose, mg/m**²
20/27		100		32		0
20/36		0		0		100
20/56		0		68		0

Characteristic	KRd (%)(n = 17)		Kd (%)(n = 31)		KMP (%)(n = 12)
Characteristic	No.	%	No.	%	No.	%
Ejection fraction reduction ≤20%		6		13		17
Age >65 y		82		68		100
Sex
Male		35		87		50
Female		65		13		50
No. of prior treatments (range)	2 (1-3)		2 (1-7)		0
NDMM		0		0		100
RRMM		100		100		0
Prior high-dose therapy		53		71		0
Prior anthracyclines		41		45		0
Bortezomib		65		84		0
Immunomodulatory imide drugs		77		87		0
Cardiovascular risk factors
Smoking		29		55		42
Hypertension		29		32		58
Coronary artery disease		6		6.5		8
Peripheral artery disease		29		23		33
Diabetes mellitus		18		23		25
Hyperlipidemia		13		12		50
Stroke		6		3		17
Arrhythmias		0		10		8
Cardiovascular disease (coronary artery disease, peripheral artery disease, stroke)		29		26		33
Medication
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers		29		19		58
Calcium channel blockers		12		13		33
Beta blockers		12		16		25
Diuretics		24		13		25
Estimated glomerular filtration rate, mL/min/1.73 m²	91		91		58
*Cafilzomib dose, mg/m**²
20/27		100		32		0
20/36		0		0		100
20/56		0		68		0

Carfilzomib dosing: 20 mg/m² on first 2 infusions followed by infusions at doses of 27 mg/m² (20/27), 36 mg/m² (20/36), or 56 mg/m² (20/56).